The Conversation (0)
BioStem Technologies (OTC: BSEM) a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine, announced today the signing of a Letter of Intent to acquire Grupo Impulso De Incentivacion Para Nuevas Tecnologías, a Mexico based, international leader in stem cell research, development, storage and therapy protocols. As quoted in …
BioStem Technologies (OTC: BSEM) a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine, announced today the signing of a Letter of Intent to acquire Grupo Impulso De Incentivacion Para Nuevas Tecnologías, a Mexico based, international leader in stem cell research, development, storage and therapy protocols.
As quoted in the press release:
GIINT is a Mexico based, biotechnology, holding company focused on innovative Regenerative Medicine through its subsidiaries, Indebioc and Store-a-Cell, and delivering treatment protocols through Clinica Franklin. GIINT utilizes stem cells that are derived from multiple sources (including dental pulp, adipose tissue, placenta, umbilical cord, bone marrow and upcoming reprogrammed IPSCs).